<DOC>
	<DOC>NCT02558959</DOC>
	<brief_summary>This study is designed to investigate the effect of second-line irinotecan and capecitabine versus irinotecan alone for gemcitabine and cisplatin refractory advanced biliary tract cancer patients.</brief_summary>
	<brief_title>Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients with histologically confirmed advanced biliary tract cancer who had experienced progression during firstline gemcitabine and cisplatin Age 18 years or older Measurable reference cancer site(s) confirmed with computed tomography (CT) or magnetic resonance imaging (MRI) Karnofsky performance status (KPS) of at least 70% Adequate renal function, adequate hepatic function, adequate bone marrow function The presence of any severe concomitant disease that could interrupt the planned treatment Intractable pain Hypersensitivity to study drugs Serious cardiovascular disease If female, pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>